
Prelude Therapeutics (PRLD) P/E Ratio
P/E Ratio as of Jun 13, 2025: -0.53
Average-0.5250
Median-0.5100
Minimum-0.6500
Maximum-0.4400
-0.53
Past Month-0.02 (3.92%)
The P/E ratio for Prelude Therapeutics (PRLD) is -0.53 as of Jun 13, 2025. This represents a decrease of -50.47% compared to its 12-month average P/E ratio of -1.07. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Prelude Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Prelude Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Prelude Therapeutics to industry peers.
Prelude Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Prelude Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Prelude Therapeutics to industry peers.
Prelude Therapeutics (PRLD) P/E Ratio Insights
See Prelude Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Prelude Therapeutics (PRLD)
Order type
Buy in
Order amount
Est. shares
0 shares
Prelude Therapeutics (PRLD) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $0.9071 | -0.50 |
May 1, 2025 | $0.9184 | -0.50 |
Apr 1, 2025 | $0.7703 | -0.42 |
Mar 3, 2025 | $0.684 | -0.36 |
Feb 3, 2025 | $1.11 | -0.58 |
Jan 2, 2025 | $1.25 | -0.66 |
Prelude Therapeutics (PRLD) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -0.53 | -20.90% |
2024 | -0.67 | -65.99% |
2023 | -1.97 | -17.57% |
2022 | -2.39 | -54.56% |
2021 | -5.26 | -90.42% |
2020 | -54.93 | — |
FAQs About Prelude Therapeutics (PRLD) P/E ratio
The latest P/E ratio of Prelude Therapeutics (PRLD) is -0.53, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Prelude Therapeutics’s last 12-month average P/E ratio is -1.07, compared to its current P/E ratio of -0.53. This reflects a decrease of -50.47%.
Prelude Therapeutics’s current P/E ratio of -0.53 is lower than its last 12-month average P/E of -1.07. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Prelude Therapeutics’s average P/E ratio over the last 3 years is -1.75. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Prelude Therapeutics’s average P/E ratio over the last 5 years is -8.81. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.